Xenon Pharmaceuticals (Xenon Pharmaceuticals) Margin of Safety % (DCF FCF Based) : N/A (As of May. 14, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Xenon Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Xenon Pharmaceuticals's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Xenon Pharmaceuticals's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenon Pharmaceuticals's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's Margin of Safety % (DCF FCF Based) falls into.

Xenon Pharmaceuticals Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Xenon Pharmaceuticals (Xenon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (NAS:XENE) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

XP0:Germany

Address

200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8

Website

https://www.xenon-pharma.com

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Executives

Gary Patou	director
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Gillian Cannon	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Justin D. Gover	director	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Patrick Machado	director	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Elizabeth A. Garofalo	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Steven Gannon	director	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
Simon N. Pimstone	director	200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Ian Mortimer	director, officer: PRESIDENT & CEO	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Christopher John Kenney	officer: Chief Medical Officer	200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W
Andrea Difabio	officer: Chief Legal Officer	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Sherry Aulin	officer: Chief Financial Officer	200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W
Sherrington Robin	officer: SVP Bus. & Corp. Development	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
James R. Empfield	officer: SVP, Drug Discovery	200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W
Seggern Christopher Von	officer: Chief Commercial Officer	200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W